Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that its Phase Ib/II study of ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of ...
If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the ...
Evidence was from an unpublished phase 3 study (n=343) in people with rheumatoid arthritis, which was included in the European public assessment report (EPAR) for Remsima (subcutaneous). For the ...
Please provide your email address to receive an email when new articles are posted on . Opdivo was previously only available intravenously. The approval comes after CHECKMATE-67T study results. Opdivo ...
Rituximab subcutaneous injection (MabThera, Roche Products Limited) was granted a marketing authorisation in March 2014 for treating non-Hodgkin's lymphoma in adults. Rituximab concentrate for ...
The subcutaneous route allows drugs such as insulin and heparin to be absorbed slowly over a period of time. Using the correct injection technique and selecting the correct site will minimise the risk ...
The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...
Enable Injections announced today that it received a commitment from Sanofi for a $30 million investment to drive growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback